Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shijiazhuang Pharmaceutical Group Receives EDQM Certification For Vitamin B12

This article was originally published in PharmAsia News

Executive Summary

Shijiazhuang Pharmaceutical Group has gained an on-site inspection certification for its vitamin B12 from the European Directorate for the Quality of Medicines, making it the first in China's vitamin B12 industry. The endorsement will allow China-made vitamin B12 to enter the high-end pharmaceutical field in 34 countries for manufacturing and sale. The potential market expansion and economic benefit represents major progress for local products which hitherto got little profit from the feedstuff and food industry. To avoid vicious competition in the low-end market, Shijiazhuang Pharmaceutical recently stepped up its international certification and registration efforts; it has already received EU Certificate of Suitability for six products - vitamin C, vitamin B12, caffeine, ranitidine, theophylline and amoxicillin. (Click her for more - Chinese Language)

You may also be interested in...

Warning Letter Close-Outs – March 2020

The US FDA released five device-related close-out letters in March.

Medicines Must Be Designated As Priority Items, Says IGBA

Governments around the world should designate all medicines as ‘priority essential products’, the IGBA has urged, as a surge in demand coinciding with a reduction in the number of flights and rising freight costs are making it more difficult for suppliers to meet global requirements amid the coronavirus pandemic.

COVID-19: FDA Will Hold Remote Meetings With Firms, Extends Marketing Application Due Dates

In a letter to the medtech industry, the FDA’s William Maisel says the US agency will hold remote meetings with device makers and other stakeholders through the end of May. The FDA also extended due dates for marketing applications by 90 days.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts